Products & Services Investor relations
About Cerep News Events & MeetingsContacts Downloads FAQs
Cerep home
Your data onlineCatalog online
Home > News > Press releases
Press releases
Risk Disclosure :
These press releases are provided for your convenience only and are not necessarily updated.
They may contain forward-looking information which is subject to risks and uncertainties that
could cause the actual results to differ materially. Factors that may affect future operations
and business of the company are described in the prospectus relating to the company’s public
offering or in the company’s annual report.

2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004-1998
December 20
 Cerep announces interim results of Phase I/II trial for its anti cancer drug
December 14
 A second compound discovered by Cerep and Bristol-Myers Squibb in phase I clinical trials
November 8
 Third quarter 2005 consolidated results
September 29
 First half-year 2005 consolidated results
August 12
 Half year 2005 consolidated sales revenues
May 13
 First quarter 2005 consolidated sales revenues
25 March
 2004 Consolidated results
14 February
 Cerep signs an agreement with Sanofi-Synthelabo Recherche for the supply of compound libraries
10 February
 2004 consolidated sales revenues
24 January
 Successfully completed Phase I for the LFA-1 antagonist by Cerep and Bristol-Myers Squibb (BMS) for the treatment of immuno-inflammatory disorders

Press releases
New products
& services

Publications
Poster presentations
Journal publications
Other
Français :: Chinese :: Home :: Site map :: Legal notice :: Credits ::